CHRONIC MYELOID LEUKAEMIA (CML): BCR-ABL KINASE DOMAIN SEQUENCING

Variants in the BCR-ABL kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia patients.

Guidelines for the use of BCR-ABL variant testing in chronic myeloid leukaemia have been published by an expert panel on behalf of the European Leukemia Net (Soverini 2011 Blood 118,5:1208-1215).

BCR-ABL kinase domain variants are identified by bi-directional Sanger sequencing which will detect variants present at a level of greater than 10%.

Laboratory contact: Dr. Caroline Wickham 01392 408252 caroline.wickham@nhs.net

Clinical contact: Dr. Paul Kerr 01392 402917 paul.kerr1@nhs.net

The laboratory participates in the NEQAS BCR-ABL1 Kinase Domain programme (Not Accredited).